Respiratory syncytial virus (RSV)– associated lower respiratory tract disease (LRTD) prevention: 1. Pregnant patients 32 through 36 weeks' gestation 2. Adults 50 to 74 years of age who are at increased risk of severe RSV disease 3. Adults 18 to 49 years of age who are at increased risk of LRTD caused by RSV

Active Immunization : Abrysvo induces an immune response against RSV preF that protects against LRTD caused by RSV. Passive Immunization : Antibodies to RSV antigens from individuals vaccinated in pregnancy are transferred transplacentally to protect infants younger than 6 months of age against LRTD and severe LRTD caused by RSV.

A single dose of RSV vaccine provides protection for at least 2 RSV seasons.

History of severe allergic reaction (e.g., anaphylaxis) to any component of Abrysvo.

The Advisory Committee on Immunization Practices recommends vaccination with Abrysvo in pregnant patients 32 through 36 weeks’ gestation.

It is not known whether Abrysvo is excreted in human milk.

Nausea (12%), pain at injection site (11% to 35%), fatigue (16%), headache (13%), arthralgia (8% to 12%), myalgia (10% to 24%)

0.5 mL as a single dose IM

The safety and effectiveness of Abrysvo to prevent RSV LRTD have not been established in non-pregnant individuals younger than 18 years of age.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer’s labeling.

?? Storage Before Reconstitution : Store refrigerated at 2°C to 8°C in the original carton.?? Storage After Reconstitution :After reconstitution, administer Abrysvo immediately or store at room temperature (15°C to 30°C) and use within 4 hours.